Phase (Ph) 1 study of oral seviteronel (VT-464), a dual CYP17-Lyase (L) inhibitor and androgen receptor (AR) antagonist, in patients (pts) with advanced AR plus triple negative (TNBC) or estrogen receptor (ER) plus breast cancer (BC) Meeting Abstract

  

Authors:	Bardia, A.; Dacosta, N. A.; Gabrail, N. Y.; Lemon, S.; Danso, M. A.; Ali, H. Y.; Fleming, R. A.; Kurman, M. R.; Eisner, J. R.; Moore, W. R.; Gucalp, A.; Traina, T. A.
Abstract Title:	Phase (Ph) 1 study of oral seviteronel (VT-464), a dual CYP17-Lyase (L) inhibitor and androgen receptor (AR) antagonist, in patients (pts) with advanced AR plus triple negative (TNBC) or estrogen receptor (ER) plus breast cancer (BC)
Meeting Title:	52nd Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	34
Issue:	15 Suppl.
Meeting Dates:	2016 Jun 3-7
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2016-05-20
Start Page:	64s
Language:	English
ACCESSION:	WOS:000404665401208
DOI:	10.1200/JCO.2016.34.15_suppl.1088
PROVIDER:	wos
Notes:	Meeting Abstract: 1088 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/154883